CRISPR-Cas Innovative Strategies for Combating Viral Infections and Enhancing Diagnostic Technologies
CRISPR-Cas in Viral Diagnostics and Therapeutics
DOI:
https://doi.org/10.61919/jhrr.v4i3.1537Keywords:
CRISPR-Cas, viral diagnostics, SHERLOCK, COVID-19, viral genome editing, therapeutic interventionsAbstract
Background: CRISPR-Cas technology has transformed molecular diagnostics and therapeutic strategies for viral infections, particularly COVID-19. Its ability to precisely edit viral genomes and detect viral RNA/DNA offers a novel approach to combating persistent viral infections.
Objective: This study aimed to evaluate the diagnostic accuracy and therapeutic potential of CRISPR-Cas systems in viral infections, with a focus on COVID-19.
Methods: A systematic review and meta-analysis of 25 peer-reviewed studies were conducted, including clinical trials and experimental research. Data collection involved searching PubMed, Scopus, and Google Scholar using keywords such as "CRISPR-Cas," "viral diagnostics," and "COVID-19." Statistical analysis was performed using SPSS version 25, with pooled sensitivity and specificity estimates calculated for CRISPR-based diagnostics.
Results: CRISPR-based diagnostics, including SHERLOCK and DETECTR, achieved pooled sensitivity of 94% (95% CI: 92%-96%) and specificity of 97% (95% CI: 95%-99%) for SARS-CoV-2 detection. Therapeutic interventions using CRISPR-Cas9 showed an 84% reduction in viral replication across HIV and Hepatitis B studies (95% CI: 80%-88%).
Conclusion: CRISPR-Cas technologies demonstrate high diagnostic accuracy and therapeutic potential, particularly in resource-limited settings. Further clinical validation is needed to enhance global healthcare applications.
Downloads
References
From Encounter With a Mysterious Repeated Sequence to Genome Editing Technology. J Bacteriol. 2018;200(7)
Grissa I, Vergnaud G, Pourcel C. The CRISPRdb Database and Tools to Display CRISPRs and to Generate Dictionaries of Spacers and Repeats. BMC Bioinformatics. 2007;8:172.
Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas Immune System: Biology, Mechanisms and Applications. Biochimie. 2015;117:119-28.
Beloglazova N, Brown G, Zimmerman MD, Proudfoot M, Makarova KS, Kudritska M, et al. A Novel Family of Sequence-Specific Endoribonucleases Associated With the Clustered Regularly Interspaced Short Palindromic Repeats. J Biol Chem. 2008;283(29):20361-71.
Wiedenheft B, Sternberg SH, Doudna JA. RNA-Guided Genetic Silencing Systems in Bacteria and Archaea. Nature. 2012;482(7385):331-8.
Lillestol RK, Redder P, Garrett RA, Brugger K. A Putative Viral Defence Mechanism in Archaeal Cells. Archaea. 2006;2(1):59-72.
Makarova KS, Grishin NV, Shabalina SA, Wolf YI, Koonin EV. A Putative RNA-Interference-Based Immune System in Prokaryotes: Computational Analysis of the Predicted Enzymatic Machinery, Functional Analogies With Eukaryotic RNAi, and Hypothetical Mechanisms of Action. Biol Direct. 2006;1:7.
Suenaga T, Kohyama M, Hirayasu K, Arase H. Engineering Large Viral DNA Genomes Using the CRISPR-Cas9 System. Microbiol Immunol. 2014;58(9):513-22.
Bi Y, Sun L, Gao D, Ding C, Li Z, Li Y, et al. High-Efficiency Targeted Editing of Large Viral Genomes by RNA-Guided Nucleases. PLoS Pathog. 2014;10(5)
Agarwalla PK, Aghi MK. Oncolytic Herpes Simplex Virus Engineering and Preparation. Methods Mol Biol. 2012;797:1-19.
Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-Frequency Off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells. Nat Biotechnol. 2013;31(9):822-6.
Xu A, Qin C, Lang Y, Wang M, Lin M, Li C, et al. A Simple and Rapid Approach to Manipulate Pseudorabies Virus Genome by CRISPR/Cas9 System. Biotechnol Lett. 2015;37(6):1265-72.
Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, et al. Efficient Genome Editing in Zebrafish Using a CRISPR-Cas System. Nat Biotechnol. 2013;31(3):227-9.
Zhong Z. CRISPR-Cas System: A Feasible Solution for Getting Rid of Persistent Viral Infection? Immunity. 2014;337:816-21.
Sorek R, Kunin V, Hugenholtz P. CRISPR—A Widespread System That Provides Acquired Resistance Against Phages in Bacteria and Archaea. Nat Rev Microbiol. 2008;6(3):181-6.
Terns MP, Terns RM. CRISPR-Based Adaptive Immune Systems. Curr Opin Microbiol. 2011;14(3):321-7.
Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Snijders AP, et al. Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes. Science. 2008;321(5891):960-4.
Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 System to Disrupt Latent HIV-1 Provirus. Sci Rep. 2013;3:2510.
Kahn JS, McIntosh K. History and Recent Advances in Coronavirus Discovery. Pediatr Infect Dis J. 2005;24(11 Suppl)
Fehr AR, Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. Methods Mol Biol. 2015;1282:1-23.
Lin H, Li G, Peng X, Deng A, Ye L, Shi L, et al. The Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses. Front Cell Infect Microbiol. 2021;11:590989.
Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: A Review of the Challenges and Approaches. Drug Deliv. 2018;25(1):1234-57.
Shmakov SA, Sitnik V, Makarova KS, Wolf YI, Severinov KV, Koonin EV. The CRISPR Spacer Space Is Dominated by Sequences From Species-Specific Mobilomes. mBio. 2017;8(5)
Ganbaatar U, Liu C. CRISPR-Based COVID-19 Testing: Toward Next-Generation Point-of-Care Diagnostics. Front Cell Infect Microbiol. 2021;11:663949.
Kumar P, Malik YS, Ganesh B, Rahangdale S, Saurabh S, Natesan S, et al. CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics. Front Cell Infect Microbiol. 2020;10:576875.
Robinson PC, Liew DF, Tanner HL, Grainger JR, Dwek RA, Reisler RB, et al. COVID-19 Therapeutics: Challenges and Directions for the Future. Proc Natl Acad Sci U S A. 2022;119(15)
Bilal A, Tanvir F, Ahmad S, Kanwal N, Zulfiqar H, Ishaq R. Pharmacokinetic Properties of Bioactive Compounds of Aloe Vera Against Pregnancy-Associated Plasma Protein A (PAPP-A) Inducing Triple-Negative Breast Cancer. Kurdish Stud. 2024;12(5):157-68.
Bilal A, Iftikhar A, Awais M, Asif I, Shaheen F, et al. Examining the Association Between Pesticide Exposures and Chronic Diseases in Agricultural Workers. Remittances Rev. 2024;9(2):2153-2176.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Farzana Shahin, Aiman Ishfaq, Iqra Asif, Asif Bilal, Shan Masih, Tooba Ashraf, Bushara Umar, Rabia Ishfaq
This work is licensed under a Creative Commons Attribution 4.0 International License.
Public Licensing Terms
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license:
- You are free to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, including commercial use.
- Attribution must be given to the original author(s) and source in a manner that is reasonable and does not imply endorsement.
- No additional restrictions may be applied that conflict with the terms of this license.
For more details, visit: https://creativecommons.org/licenses/by/4.0/.
